A study investigating CLAG-M or FLAG-Ida followed by alloSCT in R/R AML or other myeloid neoplasms

Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses a study investigating the use of CLAG-M or FLAG-Ida followed by allogeneic stem cell transplantation (alloSCT) in relapsed/refractory (R/R) acute myeloid leukemia (AML) or other high-grade myeloid neoplasms. Dr Milano highlights that patients tolerated the therapy well, with non-relapse mortality of 12% and disease-free survival of 50% at one year, with higher survival rates observed in patients receiving 4-Gray total body irradiation (TBI). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.